Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison

Supportive Care in Cancer

Volumn 21, Issue 4, 2013, Pages 1097-1103

  Phillips, Kristin M ^a   Pinilla Ibarz, Javier ^b   Sotomayor, Eduardo ^b   Lee, Morgan R ^c   Jim, Heather S L ^b   Small, Brent J ^b,c   Sokol, Lubomir ^b   Lancet, Jeffrey ^b   Tinsley, Sara ^b   Sweet, Kendra ^b   Komrokji, Rami ^b   Jacobsen, Paul B ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer; Depression; Fatigue; Quality of life

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SKIN DISEASE; SLEEP;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; CASE-CONTROL STUDIES; DEPRESSION; FATIGUE; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUALITY OF LIFE; QUESTIONNAIRES; THIAZOLES; UNITED STATES; YOUNG ADULT;

EID: 84879798859     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1630-5     Document Type: Article

References (23)

1. O'Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994-1004
2. Hahn EA, Glendenning GA, Sorensen MV et al (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21(11):2138-2146
3. Aziz Z, Iqbal J, Aaqib M et al (2011) Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 52(6):1017-1023
4. Agrawal M, Garg RJ, Cortes J et al (2010) Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 5(2):70-80
5. Pinilla-Ibarz J, Cortes J, Mauro MJ (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 117(4):688-697
6. Efficace F, Baccarani M, Breccia M et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554-4560
7. Apolone G, Mosconi P (1998) The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 51(11):1025-1036
8. Jacobsen PB, Donovan KA, Small BJ et al (2007) Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer 110(8):1851-1859
9. Hann DM, Jacobsen PB, Azzarello LM et al (1998) Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 7(4):301-310
10. Broeckel JA, Jacobsen PB, Horton J et al (1998) Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 16(5):1689-1696
11. Donovan KA, Jacobsen PB, Small BJ et al (2008) Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory. J Pain Symptom Manage 36(5):480-487
12. Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385-401
13. Hann D, Winter K, Jacobsen P (1999) Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 46(5):437-443
14. Buysse DJ, Reynolds CF 3rd, Monk TH et al (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193-213
15. Carpenter JS, Andrykowski MA (1998) Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 45(1):5-13
16. Beck SL, Schwartz AL, Towsley G et al (2004) Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J Pain Symptom Manage 27(2):140-148
17. Chang VT, Hwang SS, Feuerman M et al (2000) The memorial symptom assessment scale short form (MSAS-SF). Cancer 89(5):1162-1171
18. Ware J (1993) SF-36 health survey: Manual and interpretation guide. The Health Institute, New England Medical Center, Boston
19. Ware JE, Kosinski M, Keller SD (1994) SF-36 pysical and mental health summary scales: A user's manual. The Health Institute, New England Medical Center, Boston
20. Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates
21. Gambacorti-Passerini C, Antolini L, Mahon FX et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553-561
22. Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251-2259
23. Masiello D, Gorospe G 3rd, Yang AS (2009) The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2:46